Lifeboat Foundation

Scientists at Karolinska Institutet and the University of Gothenburg have generated a web-based software, Green Listed, which can facilitate the use of the CRISPR methodology. The software is published in the journal Bioinformatics and is freely available through greenlisted.cmm.ki.se where also information texts and films are available.

Cells are very small and builds up an organism. A human has about 100 times as many cells in its body as there are people on earth. Inside a vast majority of these cells are long chains of DNA. These DNA chains affects how different cells look and behave. CRISPR is a research method that can be used to rapidly study how different portions of the DNA directly affect cells. Using this method, researchers can gain insights to the cause of diseases and give suggestions for how they can be treated.

“We use the CRISPR methodology to study both immune cells and cancer cells. The goal is to develop new treatments for patients with diseases related to the immune system, such as arthritis, as well as cancer”, says Fredrik Wermeling at the Center for Molecular Medicine (CMM), Department of Medicine, Karolinska Institutet.

In Brief

• Kawasaki is developing AI for future bikes that will give it a personality with the hopes it will help reassure drivers.
• AI is constantly being developed in new ways, ranging from the novel to the revolutionary.

Automotive company Kawasaki Heavy Industries, Ltd. (KHI) is developing next-generation motorcycles with an AI controlled-system that not only ensures safer rides, but also develops an emotional connection with the user.

The bikes use a system called the “Emotion Generation Engine and Natural Language Dialogue System”, developed by robotics teams from cocoro SB Corp. The driver can talk to the bike and it will be able to pick up cues on the rider’s emotional state and intents. In their press release, Kawasaki said that this “will open the door to a new world of unprecedented riding experiences.”

Continue reading “Kawasaki is Going Full Knightrider With Their New AI Motorcycle” »

NASA researchers have a lot of problems to work through if they want astronauts to one day set foot on Mars. One of the biggest hurdles is where these early pioneers will sleep and live, and after a day of brainstorming, engineers might have come up with a solution – a conceptual ‘ice home’ design.

Yup, NASA is looking into creating inflatable domes covered in ice for astronauts to live and work in, providing them with protection from extreme temperatures and high-energy radiation.

“After a day dedicated to identifying needs, goals, and constraints we rapidly assessed many crazy, out of the box ideas and finally converged on the current Ice Home design, which provides a sound engineering solution,” said senior systems engineer Kevin Vipavetz, from NASA’s Langley Research Centre in Virginia.

Author and robot expert Dr. David Levy explains how marriage with robots will come in the next several decades as technological and societal transformations take place.

Join us in our femto satellite project to launch the smallest satellite in the world!

Contact [email protected] for getting involved!

Tiny electric airplanes could transform air travel.

On its own, swapping conventional aircraft engines for electric motors could have significant benefits, reducing the cost of air travel and emissions per flight. But the bigger opportunity here is to make air travel practical in situations where no one would think to take an airplane today.

Back in October, Uber published a white paper describing its vision of the future small VTOL aircraft could make possible. Uber envisions a network of on-demand aircraft carrying passengers among many landing spots distributed throughout a metropolitan area. For example, right now it takes at least an hour to drive from San Jose, California, to San Francisco — and closer to two hours during rush hour. In contrast, Uber estimates, the same trip could take 15 minutes in a VTOL airplane.

Continue reading “Why Google co-founder Larry Page is pouring millions into flying cars” »

Struggling with your diet? Your microbiota could be to blame.

Your microbiota may not be on your side as you try improving your diet this New Year’s. In a study published December 29 in Cell Host & Microbe, researchers explore why mice that switch from an unrestricted American diet to a healthy, calorie-restricted, plant-based diet don’t have an immediate response to their new program. They found that certain human gut bacteria need to be lost for a diet plan to be successful.

“If we are to prescribe a diet to improve someone’s health, it’s important that we understand what microbes help control those beneficial effects,” says Jeffrey Gordon, Director of the Center for Genome Sciences and Systems Biology at Washington University in St. Louis and senior author of the paper. “And we’ve found a way to mine the gut microbial communities of different humans to identify the organisms that help promote the effects of a particular diet in ways that might be beneficial.”

Continue reading “Your microbiota’s previous dining experiences may make new diets less effective” »

Two councils, Fife and Glasgow, are investigating idea of offering everyone a fixed income regardless of earnings.

For a few lucky patients, 2016 was the year when gene therapy turned from promises to cures. The technology, long contemplated as a way to erase disease by revising people’s DNA, made big advances and began turning into a real business offering some of the world’s most expensive and revolutionary medicines.

So what is gene therapy, anyway? The US Food and Drug Administration says it’s any treatment in which a replacement gene is added to a person’s body or a disease-causing one is inactivated. That’s usually done by adding­­­­­­ new instructions to cells via billions of viruses stuffed with correct DNA strands.

It sounds complicated, and it is. Gene therapy was first tested in a person in 1990, but scary side effects turned the gene-fix idea into a scientific backwater. And the field hasn’t conquered all its problems. We started the year with the tale of Glybera, heralded as the first gene treatment ever approved that sought to correct an inherited gene error. Yet the drug came with an eye-popping price tag of $1 million and, dogged by questions over how well it works, has turned into a medical and commercial flop.

Continue reading “Gene therapy is here, and it could radically change modern medicine” »